SIM
IMVT icon

Synergy Investment Management’s Immunovant IMVT Stock Holding History

Synergy Investment Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40
Closed -$684 – 314
2025
Q1 		$684 Hold
40
– – ﹤0.01% 581
2024
Q4 		$991 Buy
+40
New +$1.14K ﹤0.01% 606

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Synergy Investment Management's IMVT Position: Q2 2025 in Review

Synergy Investment Management sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 40 shares — an estimated $684 sold.

Synergy Investment Management first reported a position in IMVT in Q4 2024 and held it in 2 quarters. The position peaked at $991 in Q4 2024. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • Synergy Investment Management reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • Synergy Investment Management sold 40 Immunovant shares in Q2 2025, an estimated $684.
  • Synergy Investment Management first reported a position in Immunovant in Q4 2024 and held it in 2 quarters.
  • Synergy Investment Management's Immunovant position peaked at $991 in Q4 2024.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Synergy Investment Management's 13F filing for Q2 2025, filed 11 Aug 2025.